Junji Ohnishi

This inventor holds 4 USPTO granted patents. Top assignees: Tanaka Kikinzoku Kogyo K.k., Debiopharm S.a.. Active years: 1994-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Junji Ohnishi. Retrieved from https://idiyas.com/inventor/junji-ohnishi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 52(Granted Patents)

Company Filing History:

3 out of 372

Tanaka Kikinzoku Kogyo K.k.

Years Active: 1994-2003

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6518278 - Carcinostatic substance for compatible administration, process of administrating same and process of rapidly inspecting same (2003-02-11),

2. 5420319 - Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high (1995-05-30),

3. 5338874 - Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically (1994-08-16),

4. 5298642 - Process of optically resoluting optically active platinum complex (1994-03-29),

Title: Junji Ohnishi: Innovator in Cancer Therapies

Introduction

Junji Ohnishi is a prominent inventor based in Kanagawa, Japan, who has made significant contributions to the field of oncology through his innovative patents. With a total of four patents to his name, Ohnishi has focused on developing advanced methods and substances for cancer treatment, particularly emphasizing the compatibility and effectiveness of certain compounds.

Latest Patents

Among Junji Ohnishi's latest innovations are two notable patents related to carcinostatic substances. The first patent outlines a process for the compatible administration of a carcinostatic substance, such as 5-fluorouracil, alongside cis-oxalato (1R,2R-diaminocyclohexane) Pt (II) or similar platinum complexes. This combination enhances the anticancer properties of the carcinostatic substance, offering a promising approach to cancer therapy.

The second patent focuses on a specific cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex that exhibits high optical purity and minimal toxicity, proving its efficacy in anticancer treatments. This complex boasts an exceptional optical purity of 99.94% or more and has a melting point range of 198.3°C to 199.7°C. The compound is synthesized using trans-1-1,2-cyclohexanediamine or its derivatives, refined through high-performance liquid chromatography.

Career Highlights

Ohnishi has been associated with reputable organizations including Tanaka Kikinzoku Kogyo K.K. and Debiopharm S.A., where he has played pivotal roles in research and development. His work in these companies has significantly contributed to advancements in pharmaceutical formulations and cancer therapeutics.

Collaborations

Throughout his career, Junji Ohnishi has collaborated with esteemed professionals such as Koji Okamoto and Chihiro Nakanishi. These partnerships have facilitated the exchange of knowledge and expertise, further enriching Ohnishi's contributions to medical science.

Conclusion

With a career characterized by innovation and collaboration, Junji Ohnishi stands out as a key figure in the advancement of cancer treatment research. His patents offer hope for improved cancer therapies, illustrating the transformative potential of scientific ingenuity in combating one of the world's most challenging diseases.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]